23.11
0.09 (0.39%)
Previous Close | 23.02 |
Open | 23.03 |
Volume | 14,365,277 |
Avg. Volume (3M) | 17,359,061 |
Market Cap | 44,259,581,952 |
Price / Earnings (TTM) | 40.54 |
Price / Earnings (Forward) | 17.57 |
Price / Sales | 2.70 |
Price / Book | 4.09 |
52 Weeks Range | |
Earnings Date | 24 Oct 2024 - 28 Oct 2024 |
TTM Dividend Yield | 3.48% |
Profit Margin | 7.23% |
Operating Margin (TTM) | 17.87% |
Diluted EPS (TTM) | 0.570 |
Quarterly Revenue Growth (YOY) | -0.30% |
Quarterly Earnings Growth (YOY) | -86.50% |
Total Debt/Equity (MRQ) | 84.56% |
Current Ratio (MRQ) | 0.990 |
Operating Cash Flow (TTM) | 2.35 B |
Levered Free Cash Flow (TTM) | 1.99 B |
Return on Assets (TTM) | 6.97% |
Return on Equity (TTM) | 10.55% |
Market Trend
Short Term | Medium Term | ||
Industry | Household & Personal Products (US) | Bearish | Mixed |
Household & Personal Products (Global) | Bearish | Mixed | |
Stock | Kenvue Inc. | Bullish | Bullish |
Stockmoo Score
Analyst Consensus | 1.5 |
Insider Activity | NA |
Price Volatility | -5.0 |
Technical Moving Averages | -1.0 |
Technical Oscillators | -0.5 |
Average | -1.25 |
Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power. |
|
Sector | Consumer Defensive |
Industry | Household & Personal Products |
Investment Style | Mid Core |
% Held by Insiders | 0.02% |
% Held by Institutions | 102.11% |
52 Weeks Range | ||
Price Target Range | ||
High | 27.00 (Jefferies, 16.83%) | Buy |
Median | 24.00 (3.85%) | |
Low | 21.00 (Piper Sandler, -9.13%) | Hold |
Average | 24.00 (3.85%) | |
Total | 3 Buy, 2 Hold | |
Avg. Price @ Call | 21.79 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
JP Morgan | 11 Oct 2024 | 25.00 (8.18%) | Buy | 21.46 |
22 Jul 2024 | 22.00 (-4.80%) | Buy | 18.23 | |
Jefferies | 24 Sep 2024 | 27.00 (16.83%) | Buy | 23.11 |
RBC Capital | 24 Sep 2024 | 24.00 (3.85%) | Hold | 23.11 |
Piper Sandler | 23 Sep 2024 | 21.00 (-9.13%) | Hold | 23.02 |
Deutsche Bank | 25 Jul 2024 | 23.00 (-0.48%) | Buy | 18.25 |
No data within this time range.
Date | Type | Details |
---|---|---|
18 Oct 2024 | Announcement | Kenvue to Announce Third Quarter 2024 Results on November 7, 2024 |
17 Oct 2024 | Announcement | Kenvue Declares Quarterly Cash Dividend |
23 Sep 2024 | Announcement | Kenvue Drives Climate Action Strategy Forward |
23 Aug 2024 | Announcement | Kenvue Announces Participation in the Barclays Global Consumer Staples Conference |
15 Aug 2024 | Announcement | Kenvue Introduces Patented Micro-Peptide Technology with Neutrogena® Collagen Bank™ Launch |
06 Aug 2024 | Announcement | Kenvue Reports Second Quarter 2024 Results |
31 Jul 2024 | Announcement | Kenvue Announces Board Changes with Two New Independent Directors |
25 Jul 2024 | Announcement | Kenvue Increases Quarterly Cash Dividend |
TTM Dividend Yield | 3.48% |
1Y Average Dividend Yield | 1.86% |
Payout Ratio | 140.35% |
Expected Next Dividend Payment | Nov 2024 |
Ex Date | Announcement Date | Payment Date | Details |
---|---|---|---|
14 Aug 2024 | 25 Jul 2024 | 28 Aug 2024 | 0.205 Cash |
07 May 2024 | 25 Apr 2024 | 22 May 2024 | 0.2 Cash |
13 Feb 2024 | 25 Jan 2024 | 28 Feb 2024 | 0.2 Cash |
07 Nov 2023 | 26 Oct 2023 | 22 Nov 2023 | 0.2 Cash |
25 Aug 2023 | 20 Jul 2023 | 07 Sep 2023 | 0.2 Cash |
Annual Dividend Yield
Year | Annual Dividend ($) | Frequency/Year | Yield % |
---|---|---|---|
2024 | 0.605 | 3 | 2.62 |
2023 | 0.400 | 2 | 1.86 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |